金沙(8888js-官方JS认证)-Made in China

Be the most trusted biotech company

2019-11-26

First China-Manufactured Trastuzumab Biosimilar HLX02 Global Phase 3 Trial Met Primary Endpoint in Breast Cancer
2019-11-06

Henlius 汉利康®（Rituximab Injection）Wins“Biosimilar Initiative of the Year” at Global Generics & Biosimilars Awards 2019
2019-10-31

Henlius Anti-HER2 Monoclonal Antibody HLX11 Received IND Application Acceptance Notification from NMPA
2019-10-17

Henlius Innovative Anti-cMET Monoclonal Antibody HLX55 Received Clinical Approval from NMPA
2019-10-12

The breakthrough of China-manufactured trastuzumab biosimilar (HLX02) for metastatic breast cancer︱Interview of Prof. Binghe Xu and Prof. Igor Bondarenko at ESMO Congress 2019
2019-10-09

Top Dialogue | Prof. Yuankai Shi &. Prof. J. Fitzgibbon: Efficacy and the outlook of HLX01（Hanlikang®）in non-Hodgkin’s lymphoma.
2019-09-30

Henlius and KG Bio Enter into Exclusive License Agreement for Henlius Novel Anti-PD-1 mAb HLX10
2019-09-12

Henlius and KG Bio Announce a Collaboration for Henlius Novel Anti-PD-1 mAb HLX10 in the Asia Pacific Region
2019-09-07

The Confirmatory Phase 3 Study Results of First China-Manufactured Trastuzumab Biosimilar, HLX02, will be Presented at Both CSCO and ESMO This Year